

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

**Sub: Outcome of Board meeting held on 09.02.2023**

**Ref: Company's Letter dated 01.02.2023**

**Unit: Trimurthi Limited**

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Trimurthi Limited** at its meeting held on Thursday, the 09<sup>th</sup> day of February 2023 at 11:00 a.m. at the registered office of the Company situated at 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad - 500001, Telangana, approved the following:

1. Unaudited financial results for the quarter ended 31.12.2022. (Enclosed)
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 31.12.2022.(Enclosed)

This is for the information and records of the Exchange, please.

The meeting concluded at 4:00 p.m.

Thanking you.

For Trimurthi Limited



Arun Kumar Bhangadia  
Chairman and Managing Director  
DIN: 00021024


Encl. as above

TRIMURTHI LIMITED  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.  
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER III AND NINE MONTHS ENDED 31ST DECEMBER 2022

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
<b>1. INCOME</b>						
INCOME FROM OPERATIONS	42.64	4.77	9.37	53.88	77.18	84.32
OTHER INCOME	18.27	4.42	6.36	28.52	46.06	55.37
<b>TOTAL INCOME</b>	<b>60.91</b>	<b>9.19</b>	<b>15.93</b>	<b>82.20</b>	<b>123.24</b>	<b>139.49</b>
<b>2. EXPENSES</b>						
PURCHASES	64.52	3.14	8.39	71.41	105.60	129.79
COST OF MATERIALS CONSUMED			-			
MANUFACTURING EXPENSES			-			
INCREASE/(DECREASE) IN STOCK IN TRADE	(24.74)	0.75	1.82	(24.39)	(33.81)	(28.37)
RENT	0.30	0.90	-	1.20	0.80	2.10
EMPLOYEE BENEFITS EXPENSE	6.87	7.07	6.71	20.71	19.61	29.10
FINANCE COSTS		-	-			
DEPRECIATION AND AMORTISATION EXPENSES	2.47	1.03	3.36	4.21	5.49	7.16
OTHER EXPENSES	4.96	4.24	3.71	16.12	19.31	176.88
<b>TOTAL EXPENSES</b>	<b>54.38</b>	<b>17.13</b>	<b>21.99</b>	<b>89.46</b>	<b>117.06</b>	<b>296.06</b>
<b>3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2)</b>	<b>6.53</b>	<b>(7.95)</b>	<b>(8.06)</b>	<b>(7.26)</b>	<b>6.24</b>	<b>(156.58)</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>						
<b>5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4)</b>	<b>6.53</b>	<b>(7.95)</b>	<b>(8.06)</b>	<b>(7.26)</b>	<b>6.24</b>	<b>(156.58)</b>
<b>6. TAX EXPENSES</b>						
- CURRENT TAX	9.24	0.55	(6.78)	(8.10)	(8.58)	(0.55)
- TAX ADJUSTMENTS RELATING TO EARLIER YEARS			(3.39)			
- DEFERRED TAX (NET)	0.24	0.55	(3.39)	(0.10)	(0.58)	0.55
<b>7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6)</b>	<b>6.76</b>	<b>(8.50)</b>	<b>(1.28)</b>	<b>(7.36)</b>	<b>6.82</b>	<b>(156.03)</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>						
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>						
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>						
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>6.76</b>	<b>(8.50)</b>	<b>(1.28)</b>	<b>(7.36)</b>	<b>6.82</b>	<b>(156.03)</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>						
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12)</b>	<b>6.76</b>	<b>(8.50)</b>	<b>(1.28)</b>	<b>(7.36)</b>	<b>6.82</b>	<b>(156.03)</b>
(COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)						
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION):</b>						
(i) BASIC	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)
(ii) DILUTED	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION):</b>						
(i) BASIC	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)
(ii) DILUTED	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):</b>						
(i) BASIC	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)
(ii) DILUTED	0.06	(0.10)	(0.02)	(0.05)	0.06	(1.93)

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [Info@trimurthidrugs.com](mailto:Info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**

3-B-354/1106, Office No. 110G,  
Ratna Block, Raghav Ratna Towers,  
Chirag Ali Lane, Abid,  
Hyderabad, Telangana - 500 001,

# TRIMURTHI LIMITED



PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (AUDITED)
<b>A. PARTICULARS OF SHARE HOLDING</b>						
1. Public Share Holding						
- Number of Shares	2679267	2900600	2900600	2679267	2900600	2900600
- Percentage of shareholding	33.08%	35.81%	35.81%	33.08%	35.81%	35.81%
2. Promoters and promoter group shareholding						
-a. Pledged / encumbered						
-b. No. of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
-c. Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
-d. Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered						
-e. No. of Equity Shares	5420733	5199400	5199400	5420733	5199400	5199400
-f. Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-g. Percentage of Shares (of the total share capital of the company)	66.92%	66.19%	64.19%	66.92%	66.19%	64.19%

Particulars	3 Months Ended (31/12/2022)
3. Investor Complaints	
Pending at the beginning of the quarter	-Nil-
Received during the quarter	-Nil-
Disposed during the quarter	-Nil-
Remaining unresolved during the quarter	-Nil-

# TRIMURTHI LIMITED

## Segment Reporting

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2023 (AUDITED)
<b>1. Segment Revenue</b>						
a. Pharma Business	4.08	1.55	-	6.73	-	8.70
b. Financial Services	7.20	4.40	6.56	17.23	20.67	29.78
c. Investments	11.07	0.02	-	11.09	25.38	0.39
d. Trading in Shares	38.56	3.21	9.37	47.15	77.18	100.62
e. Foods	-	-	-	-	-	-
<b>Total</b>	<b>60.91</b>	<b>9.98</b>	<b>15.93</b>	<b>82.20</b>	<b>123.23</b>	<b>139.49</b>
<b>Less: Inter Segment Revenue</b>						
<b>Net Sales/ Income From Operations</b>	<b>60.91</b>	<b>9.98</b>	<b>15.93</b>	<b>82.20</b>	<b>123.23</b>	<b>139.49</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	-2.01	1.39	-	(0.46)	-	-
b. Financial Services	7.20	4.40	6.56	17.23	20.67	15.05
c. Investments	11.07	0.02	-	11.09	25.38	(349.54)
d. Trading in Shares	-9.73	(13.77)	(14.62)	(35.12)	(39.82)	(22.89)
e. Foods	-	-	-	-	-	-
<b>Total</b>	<b>6.53</b>	<b>(7.96)</b>	<b>(8.06)</b>	<b>(7.26)</b>	<b>6.23</b>	<b>(156.58)</b>
<b>Less:</b>						
i. Interest	-	-	-	-	-	-
ii. Other Un-allocable expenses net off	-	-	-	-	-	-
iii. Un-allocable Income	-	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>6.53</b>	<b>(7.96)</b>	<b>(8.06)</b>	<b>(7.26)</b>	<b>6.23</b>	<b>(156.58)</b>
<b>3. Capital Employed</b>						
a. Pharma Business	40.18	70.38	29.50	40.18	29.50	29.50
b. Financial Services	104.82	99.41	202.05	104.82	202.05	301.63
c. Investments	203.20	203.20	29.32	203.20	29.32	43.92
d. Trading in Shares	368.75	358.38	326.30	368.75	326.30	349.25
e. Foods	-	-	-	300.00	300.00	-
<b>Total</b>	<b>716.95</b>	<b>711.35</b>	<b>887.17</b>	<b>716.95</b>	<b>887.17</b>	<b>724.38</b>

## Notes

1. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

2. The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 09-02-2023.

3. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

4. The results are also available on the website of the Company.

5. During the Quarter company has sold its 100% equity shares of Trimurthi Pharmaceuticals (India) Private Limited, wholly owned subsidiary, as such it ceased to be the subsidiary of Trimurthi Limited. The company has obtained the necessary consent from shareholders and complied the provisions of the companies Act, 2013.

Place: Hyderabad  
Date: 09-03-2023

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**

53-354/1106, Office No. 1106,  
Retha Block, Raghav Ratna Towers,  
Chirag Ali Lane, Abid,  
Hyderabad, Telangana - 500 001.



## P.MURALI & CO.,

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
Info@pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Website : [www.pmurali.com](http://www.pmurali.com)

Review report to  
The Board of Directors  
Trimurthi Limited

We have reviewed the accompanying statement of unaudited financial results of TRIMURTHI LIMITED (the "Company") for the quarter ended 31<sup>st</sup> December, 2022 and for the period from 01 April 2022 to 31 December 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P.MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : [www.pmurali.com](http://www.pmurali.com)

**Emphasis of Matter Paragraph:**

As disclosed in Note no. 5 to the financial results, During this quarter under review the company has sold its wholly owned subsidiary Trimurthi pharmaceuticals (India) private limited.

Our opinion is not modified in respect of the above matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

A.KrishnaRao  
Partner  
M.No. 020085  
UDIN: 23020085BGQWZN6016



Place: Hyderabad  
Date: 09-02-2023.